Whitfield Represents Bristol-Myers Squibb on $90B Acquisition of Celgene Corporation
Overview
The feature reports an agreement for Bristol-Myers Squibb to acquire Celgene through a combination of shares and cash.
Transaction value
The stated enterprise value is $90 billion. This is the acquisition’s valuation measure, not legal fees, compensation to a claimant or recovered assets.
Business context
The account places the proposed combination in oncology, immunology and inflammation, and cardiovascular treatment. It says the combined portfolio would include nine products with annual sales above $1 billion.
Participants
The identified listed companies are Bristol-Myers Squibb, then NYSE: BMY, and Celgene, then NASDAQ: CELG. The feature attributes the advisory role to the source firm.
Related Pages
Global and Regional M&A Reports 2018Whitfield Counsels Discovery II on $1B Commitment from StonepeakWhitfield Represents Pelican Energy Partners on Investment in Axon Pressure ProductsWhitfield Represents Cloverleaf Cold Storage and Blackstone in Merger with Zero Mountain, Inc.Whitfield’s New Dallas Office Closes Two Energy Deals This Week With Combined Value of Nearly $2 Billion
